Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice

Leukemia

Volumn 23, Issue 8, 2009, Pages 1446-1454

  Chen, Y ^a   Hu, Y ^b   Michaels, S ^c   Segal, D ^c   Brown, D ^c   Li, S ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c ChemGenex Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; DASATINIB; HEAT SHOCK PROTEIN 90; HOMOHARRINGTONINE; IMATINIB; OMACETAXINE MEPESUCCINATE; PLACEBO; PROTEIN MCL 1; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LEUKEMIA; BAGG ALBINO MOUSE; CANCER SURVIVAL; CELL KILLING; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; WILD TYPE;

EID: 68749110580     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2009.52     Document Type: Article

References (22)

1. Michor F, Hughes TP, Iwasa Y, Branford S, Shah NP, Sawyers CL et al Dynamics of chronic myeloid leukaemia. Nature 2005; 435: 1267-1270.
2. Rousselot P, Huguet F, Rea D, Legros L, Cayuela JM, Maarek O et al Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007; 109: 58-60.
3. Jorgensen HG, Holyoake TL. Characterization of cancer stem cells in chronic myeloid leukaemia. Biochem Soc Trans 2007; 35 (Part 5): 1347-1351.
4. Copland M, Pellicano F, Richmond L, Allan EK, Hamilton A, Lee FY et al. BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. Blood 2008; 111: 2843-2853.
5. Konig H, Holyoake TL, Bhatia R. Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606. Blood 2008; 111: 2329-2338.
6. Kantarjian HM, Talpaz M, Santini V, Murgo A, Cheson B, O'Brien SM. Homoharringtonine: History, current research, and future direction. Cancer 2001; 92: 1591-1605.
7. Luo CY, Tang JY, Wang YP. Homoharringtonine: A new treatment option for myeloid leukemia. Hematology 2004; 9: 259-270.
8. Quintas-Cardama A, Kantarjian H, Garcia-Manero G, O'Brien S, Faderl S, Estrov Z et al. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer 2007; 109: 248-255.
9. Li S, Ilaria Jr RL, Million RP, Daley GQ, Van Etten RA. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med 1999; 189: 1399-1412.
10. Pear WS, Miller JP, Xu L, Pui JC, Soffer B, Quackenbush RC et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 1998; 92: 3780-3792.
11. Finer MH, Dull TJ, Qin L, Farson D, Roberts MR. kat: A high-efficiency retroviral transduction system for primary human T lymphocytes. Blood 1994; 83: 43-50.
12. Roumiantsev S, de Aos IE, Varticovski L, Ilaria RL, Van Etten RA. The src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase. Blood 2001; 97: 4-13.
13. Zhang CC, Lodish HF. Murine hematopoietic stem cells change their surface phenotype during ex vivo expansion. Blood 2005; 105: 4314-4320.
14. de Haan G, Weersing E, Dontje B, van Os R, Bystrykh LV, Vellenga E et al. In vitro generation of long-term repopulating hematopoietic stem cells by fibroblast growth factor-1. Dev Cell 2003; 4: 241-251.
15. Hu Y, Liu Y, Pelletier S, Buchdunger E, Warmuth M, Fabbro D et al. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet 2004; 36: 453-461.
16. Hu Y, Swerdlow S, Duffy TM, Weinmann R, Lee FY, Li S. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Proc Natl Acad Sci USA 2006; 103: 16870-16875.
17. Peng C, Brain J, Hu Y, Goodrich A, Kong L, Grayzel D et al. Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells. Blood 2007; 110: 678-685.
18. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038-1042.
19. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R et al Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354: 2531-2541.
20. Legros L, Hayette S, Nicolini FE, Raynaud S, Chabane K, Magaud JP et al. BCR-ABL(T315I) transcript disappearance in an imatinib-resistant CML patient treated with homoharringtonine: A new therapeutic challenge? Leukemia 2007; 21: 2204-2206.
21. Aichberger KJ, Mayerhofer M, Krauth MT, Skvara H, Florian S, Sonneck K et al. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): Evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood 2005; 105: 3303-3311.
22. Kantarjian HM, Cortes J. New strategies in chronic myeloid leukemia. Int J Hematol 2006; 83: 289-293.